Orencia (Abatacept)

Abatacept selectively binds to CD80 and CD86 on antigen‑presenting cells, blocking the CD28 co‑stimulatory signal needed for full T‑cell activation. This interruption reduces cytokine release and dampens the autoimmune response that drives inflammation in affected joints.

The dosing regimen for Orencia is individualized by the prescribing clinician based on factors such as body weight, disease severity and prior therapy. Healthcare providers determine the appropriate infusion schedule and any subsequent subcutaneous dosing.

Safety data for abatacept in pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Orencia product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and import documentation.

Orencia (abatacept) is a T‑cell co‑stimulation blocker, whereas many alternatives such as TNF‑α inhibitors target cytokines directly. Clinical studies suggest comparable efficacy in reducing disease activity, with a distinct safety profile that may be preferable for patients with a history of infections or who have not responded to TNF blockers.

Orencia should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until ready for use to maintain stability.

Orencia is given as an intravenous infusion, typically over a period of about 30 minutes. After the initial loading phase, patients may transition to a sub‑cutaneous formulation for maintenance dosing, as directed by their healthcare provider.

The most serious risks include severe infections such as pneumonia or tuberculosis, the potential development of malignancies, and rare neurological conditions like progressive multifocal leukoencephalopathy. Patients should be monitored closely for signs of infection or unusual symptoms.

Orencia is contraindicated in individuals with known hypersensitivity to abatacep t or any of its excipients, and it should be avoided in patients with active, uncontrolled infections. Clinicians must also assess suitability for patients with severe heart failure or those receiving live vaccines.